New Drug Could Help Kids With MS
The first drug approved for use in children with MS reduced relapse rates by 82 percent in people aged 10 to 17 compared with interferon beta-1a, a drug commonly used to slow the progression of the degenerative nerve disease. (Source: WebMD Health)
Source: WebMD Health - September 13, 2018 Category: Consumer Health News Source Type: news
Fingolimod Cuts Multiple Sclerosis Relapses in Pediatric Patients
WEDNESDAY, Sept. 12, 2018 -- Among pediatric patients with relapsing multiple sclerosis, fingolimod is associated with a lower rate of relapse but a higher rate of serious adverse events than interferon beta-1a, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - September 12, 2018 Category: Pharmaceuticals Source Type: news
Improved Disability, Cognition With Ocrelizumab in MS Improved Disability, Cognition With Ocrelizumab in MS
Extension data from phase 3 clinical trials show greater improvements in patients who continued receiving ocrelizumab than in those who switched from interferon beta-1a.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 4, 2018 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS
Breakthrough Therapy designation can expedite the development and review of therapies for serious conditions(1)
In a pivotal Phase III study, oral fingolimod significantly reduced relapses by 82% in a pediatric patient population vs. interferon beta-1a ... Biopharmaceuticals, Neurology, FDA Novartis, Gilenya, Fingolimod, multiple sclerosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 18, 2017 Category: Pharmaceuticals Source Type: news
John Walsh, M.D. Joins EMD Serono as Vice President of Neurology and Immunology, US Medical Affairs
ROCKLAND, Mass., Dec. 7, 2017 -- (Healthcare Sales & Marketing Network) -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany in the US and Canada, today announced the appointment of John Walsh, M.D. as Vice President, Neurology ... Biopharmaceuticals, Personnel EMD Serono, Merck KGaA, Rebif, interferon (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - December 7, 2017 Category: Pharmaceuticals Source Type: news
Ocrelizumab Linked to Improved Visual Outcomes in Relapsing MS Ocrelizumab Linked to Improved Visual Outcomes in Relapsing MS
In pooled analysis from the phase 3 OPERA trials, low-contrast letter acuity showed improved visual outcomes in MS after treatment with ocrelizumab over interferon beta-1a.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 27, 2017 Category: Consumer Health News Tags: Neurology & Neurosurgery News Source Type: news
The Non-Pharma Pharma Company?
Across all industries, consumers are demanding more and companies are responding, adapting their commercial models in efforts to meet their customers ’ evolving needs.Pharma is not immune to these wider changes and most companies are actively rethinking the traditional model to ensure they can compete in an increasingly multi-channel, multi-stakeholder environment.Healthcare is going through an “amazing transformation process” driven by new media, says Tim Kneen, Executive President at Merck. “The standard pharma business model of high volume, get access, make as much noise as possible will not be relevant going fo...
Source: EyeForPharma - June 29, 2017 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news
The Non-Pharma Pharma Company?
Across all industries, consumers are demanding more and companies are responding, adapting their commercial models in efforts to meet their customers ’ evolving needs.Pharma is not immune to these wider changes and most companies are actively rethinking the traditional model to ensure they can compete in an increasingly multi-channel, multi-stakeholder environment.Healthcare is going through an “amazing transformation process” driven by new media, says Tim Kneen, Executive President at Merck. “The standard pharma business model of high volume, get access, make as much noise as possible will not be relevant going fo...
Source: EyeForPharma - June 29, 2017 Category: Pharmaceuticals Authors: Danielle Barron Source Type: news
Celgene's multiple sclerosis drug succeeds in late-stage trial
(Reuters) - Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal of reducing annualized relapse rate, when compared to Biogen Inc's Avonex, in a second late-stage study. (Source: Reuters: Health)
Source: Reuters: Health - May 22, 2017 Category: Consumer Health News Tags: healthNews Source Type: news
Federal investigators subpoena Biogen over MS drug prices
Biogen (NSDQ:BIIB) said on Thursday that it received a subpoena in December last year from federal investigators about the prices of its top-selling multiple sclerosis drugs, Tecfidera, Avonex, Tysabri and Plegridy.
In its annual regulatory filing, the company wrote that the investigators inquired about “government price reporting, rebate payments and Biogen’s co-pay assistance programs.” While Cambridge, Mass.-based Biogen said it was cooperating with the federal probe, it did not provide any other specific details.
Get the full story at our sister site, Drug Delivery Business News.
The post Federal ...
Source: Mass Device - February 3, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Legal News Neurological Pharmaceuticals Wall Street Beat Biogen Source Type: news
Biogen subpoenaed by federal government over MS drug prices
Biogen disclosed Thursday that it received a subpoena late last year from federal investigators related to the price of its top multiple sclerosis drugs, including blockbuster treatment Tecfidera.
Cambridge-based Biogen (Nasdaq: BIIB) said in its annual federal filing that it had received a subpoena on Dec. 5 seeking information regarding "government price reporting, rebate payments and Biogen's co-pay assistance programs" for MS drugs Tecfidera, Avonex, Tysabri and Plegridy. The company sa id it… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - February 2, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news
